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Abstract
Background: BioBrick standard biological parts are designed to make biological systems easier to engineer (e.g.
assemble, manipulate, and modify). There are over 5,000 parts available in the Registry of Standard Biological Parts
that can be easily assembled into genetic circuits using a standard assembly technique. The standardization of the
assembly technique has allowed for wide distribution to a large number of users – the parts are reusable and
interchangeable during the assembly process. The standard assembly process, however, has some limitations. In
particular it does not allow for modification of already assembled biological circuits, addition of protein tags to pre-
existing BioBrick parts, or addition of non-BioBrick parts to assemblies.
Results: In this paper we describe a simple technique for rapid generation of synthetic biological circuits using
introduction of customized inserts. We demonstrate its use in Escherichia coli (E. coli) to express green fluorescent
protein (GFP) at pre-calculated relative levels and to add an N-terminal tag to GFP. The technique uses a new
BioBrick part (called a BioScaffold) that can be inserted into cloning vectors and excised from them to leave a gap
into which other DNA elements can be placed. The removal of the BioScaffold is performed by a Type IIB
restriction enzyme (REase) that recognizes the BioScaffold but cuts into the surrounding sequences; therefore, the
placement and removal of the BioScaffold allows the creation of seamless connections between arbitrary DNA
sequences in cloning vectors. The BioScaffold contains a built-in red fluorescent protein (RFP) reporter; successful
insertion of the BioScaffold is, thus, accompanied by gain of red fluorescence and its removal is manifested by
disappearance of the red fluorescence.
Conclusions: The ability to perform targeted modifications of existing BioBrick circuits with BioScaffolds (1)
simplifies and speeds up the iterative design-build-test process through direct reuse of existing circuits, (2) allows
incorporation of sequences incompatible with BioBrick assembly into BioBrick circuits (3) removes scar sequences
between standard biological parts, and (4) provides a route to adapt synthetic biology innovations to BioBrick
assembly through the creation of new parts rather than new assembly standards or parts collections.
Background
In traditional modification of organisms by cloning [1],
the emphasis has been on single gene changes that
improve the organism or make a single component
easier to study. Construction of synthetic genetic circuits
brings together many components [2,3] to accomplish
novel tasks, creating functions unobtainable through
single gene changes. De novo construction of genetic cir-
cuits encompasses the techniques that fall into two cate-
gories: techniques for construction and techniques for
optimization. Gene synthesis, though decreasing in price
[4], still remains prohibitively expensive for de novo
synthesis of complete genetic circuits [5]. Instead, either
newly synthesized, natural, or existing DNA fragments
are pieced together using DNA assembly techniques. A
variety of assembly methods now exist including idem-
potent methods [5-12], extensions to idempotent meth-
ods [13-18], ligation independent methods [3,19-21],
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matic assembly methods [24,25], and genome-scale
assembly methods [26-28]; however, regardless of how
genetic circuits are constructed, novel circuits almost
always require modification and optimization. Because
understanding of the relevant biological mechanisms
remains incomplete [29], one of the main problems in
newly assembled circuits is mismatch in the expression
levels of the components of the circuit [30]. Optimiza-
tion, thus, involves modifications of the expression levels
[4,31] to increase desired products, decrease toxic
by-products, and increase limiting reagents [32-34]. A
number of existing methods could be used to optimize
circuits by rebuilding [29] or reengineering [21,35]
them. It is desired, however, to minimize the number of
steps and permit rapid modification [35-41].
BioBrick assembly constitutes a widely used strategy
for assembly of custom genetic circuits [5]. BioBrick
parts are DNA pieces with standard sticky ends (Figure
1a and 1c). Using BioBricks, large circuits can be rapidly
assembled using a sequence of similar steps. Over 5,000
BioBrick standard biological parts are freely available to
researchers through the Registry of Standard Biological
P a r t s[ 4 2 ] .A l t h o u g hB i o B r i c k sh a v eb e e nu s e dt oc o n -
struct a large variety of genetic circuits [12,43-54], these
circuits often require optimization [44,55-59] and cur-
rently, there is no standard methodology for optimizing
BioBrick circuits.
Modification of a circuit’s ribosome binding sites
(RBSs) is an attractive method for optimization since
different strength RBSs create large changes in circuit
behavior [35] and a web-based tool is now available to
Figure 1 Desired BioBrick circuit modifications and approach with BioScaffolds. Every BioBrick standard biological part (a) consists of a
DNA sequence embedded between a “prefix” sequence (purple box) and a “suffix” sequence (yellow box). Parts may also contain scars (b),
which form when two parts, such as “A1” and “A2” in (c) are fused together using BioBrick assembly [12]. In many cases one would like to
convert an undesired scar between two parts in a BioBrick assembly into a different part or completely remove it (d). Our approach is to create
a new BioBrick part (the BioScaffold) (e). The BioScaffold can be assembled into a circuit using BioBrick assembly, but unlike normal BioBricks it
can be removed and replaced with a new part (f). In this paper we develop a single prototype BioScaffold that illustrates how BioScaffolds can
be used to either insert parts or remove scars.
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tory regions with predetermined sequences changes the
levels of protein expression [35,36] and can have dra-
matic effects on circuit performance. Optimizing Bio-
Brick circuits using modification of the RBS, however,
requires overcoming a fundamental limitation of the
BioBrick assembly method: it does not provide a way to
insert parts into the circuits once they are assembled
(Figure 1d). In this paper, we demonstrate a solution to
this problem by designing a new BioBrick part, termed
BioScaffold (Figure 1e and 1f), that can be easily excised
from intact BioBrick circuits and replaced with other
DNA sequences (e.g., RBSs). By virtue of its design,
BioScaffolds also bypass two other fundamental limita-
tions of BioBrick assembly: (1) it allows incorporation of
parts that contain the sites recognized by the enzymes
EcoRI, XbaI, SpeI, and PstI (these sites are incompatible
w i t hs t a n d a r dB i o B r i c ka s s e m b l y )a n d( 2 )i ta l l o w s
removal of a scar site (Figure 1b and 1f) with sequence
TACTAGAK (where K = G or T [60]) between BioBrick
parts (this is useful because the presence of the stop
codon sequence TAG in the scar interferes with produc-
tion of protein fusions and other modifications [11].)
To outline the design of the BioScaffold part, we first
r e v i e wah y p o t h e t i cc i r c u i tb u i l tf r o mc o m p o n e n t s“A1”
and “A2” (designated here as “A1-scar-A2”). Removal of
the scar sequence or its replacement with a custom reg-
ulatory element (e.g., a RBS) can be performed in two
steps. In the first step, excision of the scar and small
regions of “A1” and “A2” leaves “sticky ends” inside
“A1” and “A2.” These ends can then be used for the
ligation of the opening with a scar-less DNA sequence
or a short sequence that contains a custom ribosome
binding sequence. For example, if the excised region is
(10 bp of A1)-scar-(12 bp of A2), ligating the gap with
22 base pair annealed repair oligonucleotides consisting
of (10 bp A1)-(12 bp A2) forms a scar-less sequence
“A1-A2.” While the second step is easily accomplished,
the first step requires a specialized enzyme that recog-
nizes scar sequence TACTAGAK and cuts an arbitrary
10 base pairs to the left and 12 base pairs to the right of
it. Unfortunately, no enzymes that bind to the sequence
TACTAGAK and cut on both sides of the sequence
(but outside of it) are available at this time. REases that
cleave outside their recognition sites are known [61-64],
b u tn o n es a t i s f yt h es p e c i f i cr e q u i r e m e n t so ft h i sa p p l i -
cation. The evolution of an enzyme that can excise the
scar sequence TACTAGAK is in principle possible
[65-67], but not trivial.
As an alternative, one can use an existing Type IIB
or IIS REase that can cleave outside its recognition
sequence and modify the “scar region” between parts
“A1” and “A2” to introduce the recognition sequence.
Additional file 1 Table S1 lists an assortment of Type
IIB REases that cleave the target on both sides of their
recognition sequence [61,64]. Unfortunately, the clea-
vage efficiency of most Type IIB REases is low. For
example, the efficiencies of ArsI and PsrI are above
56% (e.g., for PsrI more than 70% of DNA fragments
can be ligated and 80% of these can be recut), whereas
REases commonly used in cloning experiments, such
as EcoRI and SpeI, typically have efficiencies above
90% http://www.sibenzyme.com. To facilitate selection
of the constructs that will undergo cutting (and subse-
quent ligation with an arbitrary DNA sequence), we
sought to introduce a reporter inside the excised
region. Final design of the BioScaffold part, hence,
contains two Type IIB recognition sequences placed on
either side of RFP reporter (as well as an additional
site within the RFP reporter)t h a ts e r v e sa sas e l e c t i o n
marker (Figure 2). This configuration makes it simple
to select colonies that circuits in which the BioScaffold
has been placed or excised and replaced with repair
oligonucleotides (Figure 3).
In this paper we demonstrate the utility of a BioScaf-
fold to optimize BioBrick circuits (by inserting a series
of RBS regulatory sequences)a sw e l la sf o rp r o d u c t i o n
of protein fusions. Because none of these processes can
be easily attained through use of standard BioBrick
assembly, these results demonstrate that the use of
BioScaffolds can aid in overcoming several limitations of
BioBrick assembly.
Results
Maximum excision capacity of commercially available
Type IIB REases
As described in the preceding section, the prototype
BioScaffold is primarily useful for introducing RBSs
(Circuit Tuning BioScaffold) or N-terminal protein tags
(Protein Engineering BioScaffold) into BioBrick circuits
that do not contain internal PsrI restriction enzyme
recognition sites or RFP repo r t e r s .T h u s ,av a r i e t yo f
BioScaffolds might be desirable for other applications or
for use with BioBrick circuits that contain PsrI sites or
RFP reporters. To provide a sense of the extendibility of
BioScaffolds, we examined a variety of restriction
enzymes that can cut outside their restriction enzyme
recognition sites and can thus be used to create the
cloning site within a BioScaffold. For several commer-
cially available Type IIB enzymes we have determined
the maximum number of nucleotides from the sur-
rounding parts “A1” and “A2” that can be excised using
an intermediate BioScaffold inserted between them. To
find the maximum number of excised nucleotides for
each enzyme, we align the enzyme recognition sites to
the outermost position where they can bind to the left
and right scar sequences. The resulting alignments,
shown in Additional file 1 Table S1, demonstrate that
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“A1” and the right part “A2” are 9 nucleotides into “A1”
for enzyme BaeI and 3 nucleotides (plus 2 additional
nucleotides for downstream protein parts) into “A2” for
enzymes BaeI and CspCI. When part “A2” is a protein
coding region then the last 2 nucleotides from the scar
region are included in part “A2,” since the last two
nucleotides of the scar TACTAGAK become the first 2
nucleotides of the start codon ATG.
BioScaffold notation, {w,x;y,z}
Since other BioScaffolds beyond the circuit tuning and
N-terminal protein engineering application (or for the
same function (tuning circuits) where PsrI restriction
enzyme sites or RFP reporters are present) might be
desired, we created a notation to make it simpler to
compare two BioScaffolds. We define the following
notation {w,x;y,z} to describe in condensed form the
positions of the cut sites relative to the BioScaffold: w
is the position of the left cut on the forward strand, x
is the position of the left cut on the reverse stand, y is
the position of the right cut on the forward strand,
and z is the position of right cut on the reverse strand.
The position numbering begins on the right side of the
BioScaffold part with 0 as the first position before
TACTAGAK, where numbers increase to the right,
and on the left side with -1 as the first position after
the K of TACTAGAK, where numbers increase to the
left–see Additional file 1 Table S1 for examples. The
cut sites of the prototype BioScaffold are given by
{0,5;15,10} (see Figure 2 where the excision positions
are marked above the cut sites). When referring to a
BioScaffold in BioBrick format, the notation {w,x;y,z}
assumes that the BioScaffold is in its most common
form when used with BioBricks (i.e., surrounded by a
scar sequence on either side).
Testing the BioScaffold
As a demonstration, we positioned the prototype BioS-
caffold in a synthetic circuit between a promoter and
GFP (Figure 3). Replacement of the BioScaffold with an
RBS caused this test circuit to become a GFP reporter
(containing a promoter, RBS, and GFP) that expresses
GFP within the cell (Figure 4). Alternatively, replace-
ment of the BioScaffold with a RBS-(maltose-binding
protein)-(glycine-serine) (RBS-MBP-GS) sequence cre-
ated a circuit that produced a MBP-GS-GFP fusion pro-
tein (Figure 5) that is fluorescent green and binds to
amylose resin. The prototype BioScaffold has been
designed to contain specific cut locations on either side
Figure 2 The prototype BioScaffold {0,5;15,10} embedded in the test circuit. Here, the internal structure of the prototype BioScaffold and
the locations of the associated PsrI cut sites and recognition sequences are shown. The prototype BioScaffold (part BBa_J70399 in the Registry
of Standard Biological Parts) is assembled between a promoter (BBa_R0010, which is not shown here) and GFP (BBa_E0040, which is partially
shown here). The BioScaffold contains one PsrI recognition site on either side of the RFP reporter (as well as an internal PsrI site within the RFP
reporter that is not shown). PsrI cuts into the scar on the left side of the part and GFP on the right side of the part, allowing the BioScaffold to
be replaced with RBS sequences that control the expression of GFP. When the BioScaffold is present, its internal RFP reporter circuit is also
present and should produce red fluorescent colonies. The RFP reporter circuit should be removed when the BioScaffold is removed. The cutting
profile for the BioScaffold is {0,5;15,10}, using the notation {w,x;y,z} is described in the Results section of the paper. Different BioScaffolds canb e
created with different restriction enzyme sites, reporters, or cutting profiles.
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BioScaffold will be replaced with one of several RBSs
that are designed to drive well-defined levels of expres-
sion in the downstream gene, demonstrating how BioS-
caffolds can be used to facilitate the optimization of
circuits. Alternatively, replacement of the BioScaffold
with the MBP-GS fusion protein part will demonstrate
how BioScaffolds can be used to create protein fusions.
The visual markers used in the prototype system help
track the presence of the BioScaffold (which contains an
RFP reporter) and the performance of the optimization
process (effect of different strength RBSs or a MBP-GS
fusion on the GFP reporter). Figure 3 shows graphically
the proposed replacement of the BioScaffold with repair
oligonucleotides that contain an RBS sequence, which
will affect the performance of the final GFP reporter cir-
cuit (Figure 4). Figure 5 shows that the BioScaffold can
successfully be replaced with an expressed MBP-GS
fusion, which causes the final protein fusion to gain the
property of affinity to an amylose column as well as
maintaining the fluorescence of GFP.
Excision of the BioScaffold and replacement with the RBS
and the RBS-MBP-GS sequences
Excision of the BioScaffold from the “promoter-scar-
BioScaffold-scar-GFP” composite part and ligation of
t h eR B Si n s e r tw a se x p e c t e dt oc r e a t ea“promoter-
scar-RBS-GFP” composite (where one RBS was
inserted in each of five parallel reactions). The plated
transformations of each reaction contained a mixture
of red colonies and green colonies. It was assumed
that the red colonies resulted from clones where the
BioScaffold was not excised. At the optimal concentra-
tion of vector in the cutting reaction, less than 3% per
Figure 3 Excision and selection for BioScaffold removal.H e r e ,
the prototype BioScaffold is present in a test circuit, with sequence
“promoter-scar-BioScaffold part-scar-GFP.” It is cut with the enzyme
PsrI and then replaced with a RBS sequence. The BioScaffold test
part contains a RFP expression circuit surrounded by two PsrI
recognition sites; thus, cells that contain the BioScaffold part, such
as the cells that contain the test circuit, exhibit red fluorescence. If
PsrI excises the BioScaffold part from the test circuit and an RBS is
ligated across the open gap, then the sequence “promoter-scar-RBS-
GFP” is obtained. Cells that contain this sequence exhibit green
flourescence, where the strength of the fluorescence depends on
the RBS used. To show the flexibility of the BioScaffold, it was also
replaced with a “RBS-MBP-GS” sequence to create the sequence
“promoter-scar-RBS-MBP-GS.”
Figure 4 GFP expression levels created by the different RBSs.
Sequence verified clones of the form “promoter-scar-RBS-GFP”
(a) were analyzed visually (b) and using flow cytometry (c). The
inserted RBSs were expected to drive relative translation initiation
rates of 10, 100, 1,000, 10,000, and 100,000 for the downstream
sequence GFP with the cell fluorescence proportional to the
translation initiation rate (a). Qualitative visual assessment revealed
green fluorescent intensity commensurate with the expected values
(b), although colony thickness can influence perceived intensity.
Simultaneously transformed colonies of RBS10, RBS100, and
RBS1,000 appeared light green, while RBS10,000 appeared green
and RBS100,000 appeared bright green (b). Quantitative assessment
using flow cytometry data revealed GFP intensity levels
commensurate with expected values, except for the higher than
expected translation initiation of GFP driven by RBS10 (c).
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caffold.) We picked 25 non-red clones for sequencing
(5 for each RBS insert). For 80% of the non-red clones,
sequencing showed that the RBS was inserted in place
of the BioScaffold part at the correct location with the
correct sequence. For 12% of the clones, sequencing
showed that the entire test circuit was completely
mutated out. For 8% of the clones, the sequencing
result was noisy, preventing interpretation. We specu-
late that none of the errors are due to the cutting
properties of the enzyme, but rather to selection
against the circuit or inadvertent picking of multiple
colonies. Using the same starting circuit, selection,
and circuit verification protocol, ligation of the RBS-
MBP-GS insert was expected to create a “promoter-
scar-MBP-GS-GFP” circuit where the ATG start
codon of the GFP was removed by the BioScaffold.
Expression levels of the RBSs
Colony and sequence verified clones that contain RBSs
in place of the BioScaffold part were assessed qualita-
tively and quantitatively (Figure 4). Visual analysis
demonstrated that the clones exhibited a range of green
fluorescent intensities: the lowest predicted expression
levels appeared light green and the highest expression
levels appeared bright green (Figure 4). Visual analysis is
o n l yar o u g hg u i d et oi n t e n s i t ys i n c et h en u m b e ro f
cells present in a colony could influence its appearance.
Overall, the flow cytometry data confirmed the results
from [36] using our method to introduce the RBS. Flow
cytometry data indicated that the predicted expression
levels were commensurate with the actual intensity
values except for sequence RBS10, which was expected
to produce the lowest intensity of protein fluorescence
(Figure 4). The actual expression level for RBS10 was
higher than expected; however, similar deviations are
observed by Salis, et al. [36] for low RBS translation
initiation strengths, and therefore appear to be unrelated
to the use of the BioScaffolds. If it was important to cre-
ate a circuit with low expression of GFP, we could have
performed another optimization round using RBSs with
similar but slightly different relative translation rates,
such as 8, 9, 11, and 12.
Affinity of the MBP-GS-GFP protein to an amylose column
The following observation confirmed the presence of
desired genetic product (MBP-GS-GFP) in the cells
that contained the “promoter-scar-RBS-MBP-GS-GFP”
circuit (Figure 5a): (1) cells which contained MBP-GS-
GFP exhibited strong fluorescence similar to those of
cells that contained the classic BBa_J04430 GFP repor-
ter circuit [68] (Figure 5b), (2) running a lysate from a
culture of MBP-GS-GFP cells through an amylose col-
umn led to retention of the fluorescent product, which
could only be eluted with a buffer containing maltose,
whereas for GFP cells the fluorescent product was
eluted in the wash (Figure 5c) and (3) both crude
MBP-GS-GFP lysate and eluate from the amylose col-
u m nc o n t a i n e das t r o n gb a n da t~ 6 7k D aa n daw e a k
band at ~134 kDa in a SDS page gel (Figure 5d,
“LOAD” and “ELUTE” lanes), which are the expected
sizes of a MBP-GS-GFP fusion and a MBP-GS-GFP
dimer [69,70], rather than the 40 kDa length of MBP-
GS or the 27 kDa length of GFP. The identity of the
bands was confirmed by mass spectrometry. (The con-
centric patterns seen on the gel are artifacts that come
from the glass of the scanner.)
Figure 5 Properties of GFP with an N-terminal MBP-GS fusion.
Lysate supernatants from cultures expressing GFP alone (a) or the
MBP-GS-GFP fusion (b) were applied to amylose columns. The
green fluorescent product was not retained on the “GFP” column
when column buffer was applied, but rather appeared in the first
wash eluate (c). In contrast the green fluorescent product was
retained on the “MBP-GS-GFP” column when column buffer was
applied (c). The protein purification process for MBP-GS-GFP was
monitored using SDS-PAGE: Lane 1, cell lysate ("load”); Lane 2, first
wash eluate ("wash”); Lane 3, maltose eluate ("elute”) (d). Mass
spectroscopy confirmed that the band at ~67 kDa was MBP-GS-GFP
and identified the minor contaminant at the top of Lane 3 ("elute”)
as a dimer form. The dimer is known to be a normal occurrence
with this construct [69,70].
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Use of the BioScaffold test circuit to overcome limitations
in BioBrick assembly and comparison with other methods
T h eo r i g i n a lp r o t o c o lf o rB i o B r i c ka s s e m b l yd o e sn o t
allow insertion of parts into premade assemblies and
optimization of the performance of premade circuits.
We demonstrate that BioScaffolds enable optimization
of premade circuits through insertion of RBSs of prede-
termined strength and protein fusions. Although a few
other approaches have been recently developed for the
same purpose (see below), the use of BioBricks provides
advantages and flexibility not present in these methods.
For example, Church and co-workers demonstrated
rapid evolution of circuits with RBSs using Multiplex
Automated Genome Engineering (MAGE) to create and
select for circuits with improved performance [35].
Sauro and co-workers used the Clontech In-Fusion PCR
Cloning kit to re-engineer BioBrick circuits [21] after
assembly. Substitution of the BioScaffold with RBSs pro-
vides an approach different from MAGE and In-Fusion
because the expression of proteins was manipulated
rationally using the RBS calculator [36]. In addition,
BioScaffolds can be used to insert both long and short
sequences.
BioBrick parts cannot contain restriction sites for
EcoRI, SpeI, XbaI, and PstI; thus, conversion of arbitrary
DNA sequences into BioBrick parts requires the time-
consuming and expensive process of removing these
sites from the sequence of interest. We demonstrate,
however, that this BioScaffold can be used to insert any
parts into BioBrick circuits except for those that contain
PsrI recognition sites. Importantly, PsrI recognizes
GAACNNNNNNTAC (or GTANNNNNNGTTC) and
the probability of encountering this sequence in a ran-
dom DNA sequence (once every 8,192 base pairs for the
forward or reverse recognition site) is 8 times lower
than that of encountering a site for EcoRI, SpeI, XbaI,
or PstI. In the event that the site for PsrI is present in
the insert part, it is possible to use another restriction
enzyme (see Additional file 1, Table S1) to create appro-
priate sticky ends for the insert.
Conclusions
We demonstrated that BioScaffolds could be implemen-
ted as a BioBrick part, integrated into BioBrick circuits,
and used to remove a scar sequence. Additionally, BioS-
caffolds allowed the introduction of parts directly into
preassembled circuits. This work demonstrated the
introduction of RBSs for circuit optimization, but nat-
ural sequences, BioBrick parts, or assemblies of parts
can alternately be incorporated. Specifically, appropri-
ately designed BioScaffolds allow the creation of protein
fusions or the addition of N- or C-terminal tags. For
instance, the prototype BioScaffold shown here can also
be used to add N-terminal tags, as was demonstrated
here through the introduction of a MBP fusion
upstream of GFP. Another advantage of BioScaffolds is
that a wide variety of parts can be introduced at a speci-
fic position in a single reaction, providing an approach
to perform directed evolution and selection of circuits
using BioBrick standard biological parts. Thus, BioScaf-
folds provide a compelling tool to extend idempotent
assembly techniques, such as BioBrick assembly, and
can even be utilized in combination with PCR based cir-
cuit assembly techniques.
Methods
Construction of prototype BioScaffold: part BBa_J70399
The prototype BioScaffold (BBa_J70399, the part num-
ber assigned by the Registry of Standard Biological Parts
at [42]) was created using the RFP production circuit
(BBa_J04450) as a template and the primers J70399-f
(5’-gtttcttcgaattcgcggccgcttctagagatacatgaacatgcaatacg-
caaacc-3’) and J70399-r (5’-gtttcttcctgcagcggccgctactag-
tagagagcgttcaccgacaaacaacag-3’). Each primer contains a
recognition site for the Type IIB REase PsrI as well as
the standard BioBrick ends. The reactions contained 45
μl PCR SuperMix High Fidelity (Invitrogen), 12.5
pmoles of forward and reverse primer, and 1 ng tem-
plate DNA in a 50 μl total volume. The PCR steps
included a denaturation step of 96°C for 4 minutes fol-
lowed by 36 cycles of a 94°C denaturation step for 30
seconds, a 52.3°C anneal step for 30 seconds, and a
68°C extend step for 2.5 minutes. Finally, the reactions
were incubated at 68°C for 10 minutes before being
cooled to 4°C until the reactions were halted. The sam-
ples and 1 μg of 2-log DNA ladder (New England Bio-
labs, Inc.) were electrophoresed in separate lanes on a
1% agarose gel. Sample bands of length 1000 base pairs
were excised and purified with a QIAEX II Gel Extrac-
tion Kit (QIAGEN). The amplified linear DNA fragment
was cloned into the BioBrick vector pSB1AT3, by
digesting both the fragment and the vector with XbaI
and PstI and performing the ligation using protocols
adapted from BioBricks assembly kit (New England Bio-
labs, Inc.) to place the fragment into the vector. The
ligation mixture was transformed into chemically com-
petent E. coli strain TOP10 (Invitrogen) [12] and plated
on Luria-Bertani (LB) agar plates supplemented with 15
μg/ml tetracycline and 100 μg/ml ampicillin.
Assembly of the BioScaffold test circuit: part BBa_J70423
The test circuit consists of a promoter, the BioScaffold,
and GFP assembled into the circuit “promoter-scar-
BioScaffold-scar-GFP.” T h ea s s e m b l yw a sp e r f o r m e di n
two rounds using the BioBrick Assembly kit (New Eng-
land Biolabs, Inc.) for three antibiotic (3A) assembly.
First, the promoter (BBa_R0010 in BioBrick vector
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vector pSB1AT3), and the destination vector pSB1AK3
were digested. The upstream part, the promoter
(BBa_R0010), was digested with EcoRI and SpeI. The
downstream part, the BioScaffold part (BBa_J70399), was
digested with XbaI and PstI. The destination vector
pSB1AK3 was disgested with EcoRI and PstI. The digests
were mixed together and ligated with T4 ligase, to form a
composite part (BBa_J70405 in the vector pSB1AK3).
The ligation mixture was transformed into chemically
competent TOP10 cells as above and plated on LB agar
plates containing 100 μg/ml ampicillin and 50 μg/ml
kanamycin. 5 colonies that appeared red were verified by
colony PCR and sequencing as described below.
Next, the composite part (BBa_J70405 in BioBrick vec-
tor pSB1AK3), the GFP (BBa_E0040 in BioBrick vector
pSB1A2), and the destination plasmid pSB1AC3 were
digested and ligated in the same manner as above,
where BBa_J70405 was the upstream part and
BBa_E0040 was the downstream part, to form the test
circuit composite part (BBa_J70423). The ligation mix-
ture was transformed into chemically competent TOP10
cells as above and plated on LB agar plates containing
100 μg/ml ampicillin and 35 μg/ml chloramphenicol. 5
colonies that appeared red were verified by colony PCR
and sequencing as described below.
Design of RBSs
The RBS calculator [71] was used to design the RBS
sequences. The downstream GFP (BBa_E0040) was
entered as the protein coding sequence. TACTAGAG
was used as the presequence. Five different target trans-
lation initiation rates (10, 100, 1,000, 10,000, and
100,000) were entered into the calculator to generate
the five different RBS sequences. The sequences gener-
ated by the calculator (see Table 1) were then utilized to
create forward and reverse oligonucleotides, taking into
account the cutting profile of the BioScaffold. The
forward oligonucleotide has the sequence “G-RBS
sequence-ATGCGTAAA” and the reverse oligonucleo-
tide has the sequence reverse complement of “CTA-
GAG-RBS sequence-ATGC.” After the replacement of
the BioScaffold with the annealed oligonucleotides, the
downstream scar disappears, while the upstream scar
remains.
Design of the RBS-MBP-GS insert
The RBS-MBP-GS insert was created using the plasmid
pMAL-p5e (New England Biolabs) as a template and the
primers RBS-MBP-GS-GFPstart-f (5’-gaattcgcggccgcttc-
tagagacgaacgctctctactagatgcctagagtcgccccctaagggcggagg-
taggagaaactcaaatg aaaatcgaagaaggtaaactggtaatctg -3’) and
RBS-MBP-GS-GFPstart-r (5’-ctgcagcggccgctactagtagtaa-
tatatgttcgatagattttacgagaaccagtctgcgcgtctttcagg -3’) using
the same PCR and gel extraction protocol as for
BBa_J70399.
Excision of BioScaffold part from the test circuit and
replacement with RBSs
The oligonucleotides containing the RBSs were prepared
by combining 8 μlo f1 0 0μM forward oligonucleotide,
8 μlo f1 0 0μM reverse oligonucleotide, 10 μla n n e a l i n g
buffer (100 mM Tris HCl pH 7.5, 1 M NaCl, 10 mM
EDTA), and 74 μl milliQ water. They were then
annealed by heating to 95°C for 2 minutes, ramping
from 95°C to 25°C over 45 minutes, and then cooling to
4°C. We diluted 10 μl of oligonucleotides into a final
volume of 1000 μl.
We digested the test circuit by combining 100 ng
DNA, 1× Buffer Y (SibEnzyme, Inc.), 100 μg/ml Bovine
Serum Albumin (SibEnzyme, Inc.), and 0.5 μLP s r I
(SibEnzyme, Inc.) into a final volume of 50 μl. The
restriction digest reaction was incubated for 1 hour at
30°C followed by 20 minutes at 65°C. In our experience
digestion of more DNA dramatically increases the num-
ber of undigested products yielding red colonies upon
transformation.
We performed the ligation by combining 5 μLo ft h e
PsrI digestion reaction (10 ng DNA), 0.2 μL of the diluted
annealed oligonucleotides, 1× T4 DNA ligase reaction
buffer, 200 units of T4 DNA ligase into a 20 μLt o t a l
volume and cooling to 18°C for 30 minutes. The ligation
mixture was transformed into chemically competent
TOP10 cells as above and plated on LB agar plates con-
taining100 μg/ml ampicillin and 35 μg/ml chlorampheni-
col. 5 non-red colonies per reaction were verified by
colony PCR and sequencing as described below.
Replacement of the BioScaffold with the RBS-MBP-GS
insert to create BBa_J70631
B o t ht h et e s tc i r c u i ta n dt h eg e lp u r i f i e dR B S - M B P - G S
insert were digested with PsrI as described above in
Table 1 Sequences generated by the RBS Calculator
Target Rate Sequence
10 10.5 CTAAATAGGAGGCTGGGAGTTCAACGAAACCCCT
100 95.6 CCCCCGTTCACTATACCGCAGGCCTTCTTTACAAA
1,000 950.1 ACATTAACCTACAAAGAACGTCGCAGAGGGA
10,000 9,953.7 TGTCGCGGATACTGATCCATAAAGGCCGGGGTT
100,000 94,459.0 TAGAGCCGTTAAAGAAGCTAGGAGGCCGAA
10, 100, 1,000, 10,000, and 100,000 were entered as target initiation rates in
the RBS calculator. The RBS calculator uses a relative scale to relate relative
translation initiation rate with five terms that quantify the strengths of
molecular interactions involved in this process, with the result that any RBS
sequence designed by the RBS Calculator can be related on this scale (further
descriptions of this unitless parameter are available in the document [36] and
FAQs [77,78] describing this software. Qualitatively from visual analysis of GFP
expression in our samples and quantitatively based on our FACS results, we
consider 10-100 to be low rates of translation initiation, 1,000 to be a medium
rate, and 10,000 and above to be high rates of translation initiation.
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bining 5 μl of the test circuit digestion reaction, 5 μlo f
the RBS-MBP-GS insert digestion reaction, 1× T4 DNA
ligase reaction buffer, 200 units of T4 DNA ligase into a
20 μl total volume and cooling to 18°C for 30 minutes.
The transformation and sequencing of BBa_J70631
occurred as described previously for a test circuit con-
taining an insert.
Verification with colony PCR and sequencing
Colony PCR and subsequent gel electrophoresis were
performed according to [12] except that the BioBrick
primers BioBrick-f (BBa_G1004) and BioBrick-r
(BBa_G1005) were used. The PCR protocol was the
same as described for the BioScaffold part above, except
that the extension step at 68°C occurred for 3.5 minutes
instead of 2.5 minutes. The Massachusetts Institute of
Technology Biopolymers Laboratory performed DNA
sequencing, using the verification primers VF2
(BBa_G00100) and VR (BBa_G00101).
Flow cytometry measurement of final circuit fluorescent
intensity
Expression data were collected using a Becton-Dickinson
FACSCAN flow cytometer with a 488-nm argon excita-
tion laser and a 515-545 excitation filter [72]. Cells were
grown in M9 media [73] (1× M9 salts, 2 mM MgSO4,
0.5% glycerol, 0.2% casamino acids, 2 mM thiamine) with
ampicillin and chloramphenicol. The cultures were
grown according to [74], except that the samples were
measured in M9 medium [73].
Purification of the MBP-GS-GFP protein using an amylose
column
The BBa_J70631 construct, which contains a MBP-GS-
GFP expression circuit, was expressed in E. coli Top10.
The culture was grown overnight at 37°C in rich media
(10 g typtone, 5 g yeast extract, 5 g NaCl, 2 g glucose) con-
taining 100 μg/ml ampicillin and 35 μg/ml chlorampheni-
col, expanded 1:100 the next day and grown for 3 hours
after the OD600 reached 0.6. The BBa_J04430 construct,
which contains a GFP expression circuit, was grown in the
same manner except the media did not contain chloram-
phenicol. Purification of a 40 ml culture of each construct
was performed according to [75] using amylose resin
(New England Biolabs), expect that the GFP and MBP-
GS-GFP lysates were diluted until they exhibited equiva-
lent fluorescent intensity and an equivalent volume of
each cleared lysate (containing less MBP than the binding
capacity of the amylose resin) was applied to each column.
SDS-PAGE of MBP-GS-GFP
S a m p l e sw e r er u no na4 - 1 2 %B i s - T r i sg e l( I n v i t r o g e n )
and stained with Coomassie blue or SimplyBlue
(Invitrogen) stain [76]. The contrast of the image was
adjusted uniformly in Adobe Photoshop to simplify the
visualization of the bands.
Mass spectrometry of MBP-GS-GFP
The lanes from a SimplyBlue stained SDS PAGE gel
were excised and submitted for analysis to the Proteo-
mics Core Facility of the Koch Institute for Integrative
Cancer Research at MIT. The gel bands were subjected
to in-gel protein digestion with trypsin, following stan-
dard protocols. LC-MS/MS analyses were carried out
using a nanoflow reversed phase HPLC (Agilent) and an
LTQ ion trap mass spectrometer (Thermo Electron).
Protein identifications were carried out by database
search using Sequest software (Thermo Electron) against
an E. coli protein database, generated from the Uni-
ref100 protein database. The protein sequence of the
MBP-GS-GFP fusion protein was added to the E. coli
protein database.
Identity of the bands at ~67 and ~134 kDa
Proteins in the bands at ~67 and ~134 kDa were identi-
fied by in-gel digestion and LC-MS/MS analysis.
Additional material
Additional file 1: Table S1 - BioScaffold designs for maximal
excision (see additional file). Several Type IIB enzyme recognition sites
are aligned to the scar sequence TACTAGAK to determine maximum
excision to the left and to the right of the BioScaffold. The alignment of
the recognition sites to the scar fixes the sequence at the start and end
of the BioScafffold. We include several notes to clarify the table. First, the
enzymes shown cut on both sides of their recognition site, not just one.
For example, the cut sites and recognition sequence for PsrI is (7/12)
GAACNNNNNNTAC(12/7) [64]. Second, the K (in the scar sequence
TACTAGAK) is T for any protein coding region or other sequence that
starts with ATG (i.e., TACTAGATG) and G for any other sequence. M
represents A or C, R represents G or A, and Y represents C or T [60].
Third, recognition sequences for the enzyme are highlighted in bold
font. Fourth, the internal cuts sites within the BioScaffold are not shown
and the selection marker between the two recognition sites is
represented as |...| In the prototype BioScaffold, the selection marker is a
RFP reporter circuit. Fifth, the notation represents the location of the cut
sites in condensed form. BioScaffold {w,x;y,z} notation is described in the
Results section of the paper.
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